As Regeneron Worries Rise On Eylea Combo Failure, Eyes Turn To PANORAMA
Failure of RUBY and ONYX combo trials with Eylea and nesvacumab fan concerns over longer-term growth prospects for Regeneron's ophthalmic franchise.
You may also be interested in...
Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.
Generic drug producers endured very mixed fortunes on the world's stock markets, with firms ending November at opposite ends of Scrip's Stock Scan monthly league table.